Tech Company Financing Transactions
Alector Funding Round
OrbiMed and Polaris Partners participated in a Series A venture round for Alector. The funding round closed on 11/1/2013.
Transaction Overview
Company Name
Announced On
11/1/2013
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
OrbiMed (Lead Investor) (Carl Gordon)
Polaris Partners (Lead Investor) (Terry McGuire)
Proceeds Purpose
The proceeds from this financing will enable Alector to begin research and development on innovative targets.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
131 Oyster Point Blvd. 600
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Alector (Nasdaq: ALEC) is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Tillman Gerngross
Chief Executive Officer
Arnon Rosenthal
Chief Financial Officer
Calvin Yu
Chief Medical Officer
Robert Paul
VP - Bus. Development
Robert King
VP - Bus. Development
Sabah Oney
VP - General Counsel
Stephanie Yonker
VP - Human Resources
Clare Hunt
VP - Manufacturing
Christian Simonsen
VP - Operations
Omer Siddiqui
VP - R & D
Hua Long
Browse more venture capital transactions:
Prev: 11/1/2013: eConais venture capital transaction
Next: 11/1/2013: Kumu Networks venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs